DK0868519T3 - Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser - Google Patents

Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser

Info

Publication number
DK0868519T3
DK0868519T3 DK96940870T DK96940870T DK0868519T3 DK 0868519 T3 DK0868519 T3 DK 0868519T3 DK 96940870 T DK96940870 T DK 96940870T DK 96940870 T DK96940870 T DK 96940870T DK 0868519 T3 DK0868519 T3 DK 0868519T3
Authority
DK
Denmark
Prior art keywords
aur
polypeptides
diagnosis
treatment
related disorders
Prior art date
Application number
DK96940870T
Other languages
English (en)
Inventor
Gregory D Plowman
Kevin G Mossie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26678652&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0868519(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of DK0868519T3 publication Critical patent/DK0868519T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96940870T 1995-12-18 1996-11-25 Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser DK0868519T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US880995P 1995-12-18 1995-12-18
US2394396P 1996-08-14 1996-08-14

Publications (1)

Publication Number Publication Date
DK0868519T3 true DK0868519T3 (da) 2006-05-08

Family

ID=26678652

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96940870T DK0868519T3 (da) 1995-12-18 1996-11-25 Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser

Country Status (15)

Country Link
US (2) US5962312A (da)
EP (2) EP0868519B1 (da)
JP (1) JP3944241B2 (da)
KR (1) KR100459052B1 (da)
AT (1) ATE315654T1 (da)
AU (1) AU716330B2 (da)
CA (1) CA2239692C (da)
DE (1) DE69635740T2 (da)
DK (1) DK0868519T3 (da)
ES (1) ES2255715T3 (da)
IL (1) IL124728A (da)
NO (1) NO323646B1 (da)
NZ (1) NZ323795A (da)
PT (1) PT868519E (da)
WO (1) WO1997022702A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
ATE342971T1 (de) * 1997-08-15 2006-11-15 Univ Hiroshima Den zellzyklus regulierende proteine
US5962232A (en) * 1998-01-30 1999-10-05 Incyte Pharmaceuticals, Inc. Protein kinase molecules
ES2334879T3 (es) 1999-09-21 2010-03-17 Astrazeneca Ab Derivados de quinazolina y su uso como productos farmaceuticos.
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
US6872533B2 (en) 2001-07-27 2005-03-29 The Regents Of The University Of California STK15 (STK6) gene polymorphism and methods of determining cancer risk
AU2003215460A1 (en) * 2002-03-28 2003-10-13 Qlt Inc. Cancer associated protein kinases and their uses
FR2840905B1 (fr) 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
US7444273B1 (en) * 2002-06-21 2008-10-28 Takeda San Diego, Inc. Crystallization of aurora/LPL1P-related kinase
CA2498000C (en) * 2002-09-11 2015-01-20 Genentech, Inc. Use of tumor-associated kinase (task) 110 antagonists for treating pancreatic cancers
AU2003295598B2 (en) * 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
ATE438644T1 (de) 2002-12-24 2009-08-15 Astrazeneca Ab Chinazolinderivate
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
ATE412779T1 (de) * 2003-02-20 2008-11-15 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
JP2007506442A (ja) * 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
ES2787475T3 (es) * 2003-06-24 2020-10-16 Genomic Health Inc Predicción de probabilidad de recurrencia del cáncer
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
JP2007509613A (ja) * 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US20050196782A1 (en) * 2003-12-23 2005-09-08 Kiefer Michael C. Universal amplification of fragmented RNA
EP2947160B1 (en) 2004-04-09 2017-07-12 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005118544A2 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20050282208A1 (en) * 2004-06-18 2005-12-22 Cytokinetics, Inc. Cellular phenotype
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
ATE550440T1 (de) * 2004-11-05 2012-04-15 Genomic Health Inc Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
AU2005304824B2 (en) 2004-11-05 2011-12-22 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
AU2006233537A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
WO2007030795A2 (en) * 2005-09-09 2007-03-15 Cytokinetics, Inc. Cellular phenotype
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080020412A1 (en) * 2006-01-03 2008-01-24 Romanowski Michael J Aurora expression constructs
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
JP5279063B2 (ja) * 2007-05-25 2013-09-04 国立大学法人愛媛大学 Ｈｌａ−ａ２拘束性抗原ペプチドおよびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
SG49753A1 (en) * 1991-02-22 1998-06-15 American Cyanamid Co Identification of a novel human receptor tyrosine kinase gene
JPH09501302A (ja) * 1993-04-07 1997-02-10 キャンサー リサーチ キャンペーン テクノロジー リミティド 治療活性についての物質のスクリーニングのための方法及びそれにおいて利用するための方法
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Also Published As

Publication number Publication date
DE69635740D1 (de) 2006-04-06
KR20000064437A (ko) 2000-11-06
KR100459052B1 (ko) 2005-01-15
NO982794L (no) 1998-08-18
EP0868519A1 (en) 1998-10-07
CA2239692A1 (en) 1997-06-26
EP0868519B1 (en) 2006-01-11
AU1082697A (en) 1997-07-14
IL124728A (en) 2007-06-03
US5962312A (en) 1999-10-05
CA2239692C (en) 2008-12-16
WO1997022702A1 (en) 1997-06-26
JP2000502895A (ja) 2000-03-14
ES2255715T3 (es) 2006-07-01
US5972676A (en) 1999-10-26
NO323646B1 (no) 2007-06-18
NZ323795A (en) 2000-01-28
NO982794D0 (no) 1998-06-17
JP3944241B2 (ja) 2007-07-11
DE69635740T2 (de) 2006-09-14
EP1655369A1 (en) 2006-05-10
IL124728A0 (en) 1999-01-26
AU716330B2 (en) 2000-02-24
ATE315654T1 (de) 2006-02-15
PT868519E (pt) 2006-05-31

Similar Documents

Publication Publication Date Title
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
DK1051500T3 (da) Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme
DE69117949D1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
BR9302075A (pt) Composto de aminoacido,composto de acido nucleico,vetor de acido nucleico,celula hospedeira,clone genomico,processo para diagnostico de doenca de alzheimer,teste,e processo para expressar uma sequencia de acido nucleico
WO1997048723A3 (en) Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE69841037D1 (de) Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.
ATE245699T1 (de) Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie
DE69943022D1 (de) Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ES2123582T3 (es) Proteina con capacidad de formacion de huesos y procedimiento para su produccion.
WO1999033870A3 (en) Human regulatory proteins
DE3751893D1 (de) Polypeptid und dessen Herstellung
ATE265533T1 (de) Saeugetierchemokine
WO2004042000A3 (en) 157 human secreted proteins
DE3750240D1 (de) Gen, das ein Insektizid-Protein kodiert, und Herstellung des Proteins durch Verwendung dieses Gens.
WO1996037610A3 (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
WO2002072763A3 (en) Nucleic acids, proteins, and antibodies
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.
ATE542900T1 (de) Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs